3SBio stock gained 3.02 percent as interim profit fell

Published on 10/07/2026 at 02:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Six-month net profit declined 15.6 percent year over year to RMB 1.15 billion. Revenue rose 3.9 percent to RMB 4.53 billion as licensing and CDMO income expanded.

3SBio, KYG8875G1029, Illustration mit AI erstellt.

3SBio (ISIN KYG8875G1029) was last at HKD 16.01 on the Hong Kong Stock Exchange on October 6, 2026, up 3.02 percent from HKD 15.54. The latest company report showed revenue growth alongside a decline in reported net profit.

Interim profit faces pressure

According to Moomoo on September 30, 2026, revenue for the six months ended June 30, 2026, increased 3.9 percent year over year to RMB 4.53 billion. Gross profit rose 2.1 percent to RMB 3.79 billion, but gross margin declined from 85.3 percent to 83.8 percent.

The pressure was clearer below the gross-profit line. Net profit attributable to equity shareholders declined 15.6 percent year over year to RMB 1.15 billion, while basic earnings per share stood at RMB 0.45.

Licensing and CDMO change the mix

The same interim report showed adjusted operating net profit increasing 26.5 percent to RMB 1.44 billion. Outbound licensing income reached RMB 850 million, while CDMO revenue increased 160.9 percent to RMB 230 million.

That mix shift matters because biological product sales declined 19.3 percent to RMB 3.44 billion. Research and development expenses increased 24.9 percent to RMB 680 million, equal to 15.1 percent of revenue, as 3SBio advanced projects in oncology, autoimmune disease, nephrology, metabolism and dermatology.

The report also identified healthcare payment reform, centralized procurement and exchange-rate movements as risks for the existing portfolio. It said Yisaiputuo and Xinbiao received listing approvals during the period, while Tebiao received U.S. FDA approval for overseas bridging clinical trials.

Analysts see upside to HKD 31.15

Investing.com lists a Strong Buy consensus from 13 analysts, including 12 Buy ratings, one Hold rating and zero Sell ratings. The average 12-month price target is HKD 31.15, with a high estimate of HKD 43.88927903 and a low estimate of HKD 23.88927903, according to Investing.com.

Against the HKD 16.01 price on October 6, 2026, the average target lies 94.54 percent above the stock. The contrast between that valuation view and the 15.6 percent first-half profit decline leaves licensing income, CDMO expansion and the margin trend as the key figures for assessing the next phase.

3SBio stock remains below its yearly high

3SBio stock was last at HKD 16.01 on October 6, 2026, with a 52-week range of HKD 14.81 to HKD 35.42. Its market capitalization stood at HKD 39.8 billion on the same date.